Heat Biologics to Present at the 28th Annual ROTH Conference

DURHAM, N.C., March 04, 2016 -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient’s immune system against cancer, announced that the company is scheduled to present at the 28^th Annual ROTH Conference on Tuesday, March 15, 2016 at 7:30 a.m. Pacific Time. 

The link to the live audio webcast and replay of the presentation may be accessed on Heat’s corporate website at http://ir.heatbio.com/events-presentations.  The webcast will be archived on the company’s website for a period of three months.

About Heat Biologics, Inc.
Heat Biologics, Inc. (Nasdaq:HTBX) is an immuno-oncology company developing novel therapies that activate a patient’s immune system against cancer.  Heat’s highly specific T cell-stimulating platform technologies, ImPACT and ComPACT, form the basis of its product candidates.  These platforms, in combination with other therapies, such as checkpoint inhibitors, are designed to address three distinct but synergistic mechanisms of action: robust activation of CD8+ “killer” T cells (one of the human immune system’s most potent weapons against cancer); reversal of tumor-induced immune suppression; and T cell co-stimulation to further enhance patients’ immune response.  Currently, Heat is conducting a Phase 2 trial with its HS-410 (vesigenurtacel-L) in patients with non-muscle invasive bladder cancer (NMIBC) and a Phase 1b trial with its HS-110 (viagenpumatucel-L) in combination with an anti-PD-1 checkpoint inhibitor to treat patients with non-small cell lung cancer (NSCLC).  For more information, please visit www.heatbio.com.            

CONTACT:
Heat Biologics, Inc.                                                
Jennifer Almond 
Investor and Media Relations                                                        
919-240-7133                                                           
[email protected]